A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Study Director - Scott Laurie, MD
Ottawa General Hospital Cancer Centre
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tom Baker Cancer Centre
Calgary, Alberta, Canada
- Northeast Cancer Centre, Health Sciences North
Greater Sudbury, Ontario, Canada
- Juravinski Cancer Centre
Hamilton, Ontario, Canada
- Ottawa General Hospital Cancer Centre
Ottawa, Ontario, Canada
- Princess Margaret Hospital
Toronto, Ontario, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2013
- Primary completion
- 30 Jun 2015
- Completion
- 30 Jun 2015
- Last update posted
- 17 Sept 2015
- Registered enrollment
- 12
- Registry id
- NCT01769547
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.